Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review suggests that telocytes in male reproductive organs help organize tissue structure and paracrine factors, impacting organ development and pathology, but more research is needed on their molecular pathways.

This meta-analysis found that spironolactone use was linked to a decreased risk of prostate cancer but not to a significant risk increase for several other cancers, although the evidence certainty was low.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

In this study, finasteride was found to worsen the cardiac effects but reduce the mutagenic effects of nandrolone in male Wistar rats.

This study found that for men with moderate-to-severe LUTS/BPH, 6 months of treatment with tamsulosin plus the hexanic extract of S. repens was as effective as tamsulosin plus a 5-alpha-reductase inhibitor but had better tolerability.

This case report examines the long-term impact of extensive anabolic-androgenic steroid use on metabolic and cardiovascular health, highlighting adverse effects to guide primary care for this patient group.

This study reviewed literature on dermatological changes in transgender and gender diverse individuals during gender affirming medical transition, identifying risks like acne and hypertrophic scars, and provided tailored care recommendations for health professionals.

This study identified novel mitochondrial DNA variations in PCOS patients from Pakistan, which may serve as genetic predisposition markers, highlighting especially the potential pathogenicity of frameshift mutations in the MT-ND2 gene.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This study found that finasteride treatment decreased VEGF expression in the prostate tissue of patients with benign prostatic hyperplasia, although it did not affect vascular density or serum VEGF levels.

This review discusses the development and trials of finasteride for prostate cancer prevention, reporting reduced cancer prevalence but noting concerns about increased high-grade cancer incidence.

This study found that patients with bladder outlet obstruction and moderately enlarged prostates are likely to successfully discontinue the a-blocker doxazosin after 9 months of combination therapy with finasteride.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This review explores potential indications for prolactin receptor inhibitors beyond breast and prostate cancers, emphasizing the need for potent antibodies to further research prolactin receptor expression.

This study found that finasteride improved urodynamic measures of obstruction in men with benign prostatic enlargement and lower urinary tract symptoms, with continued improvement over two years of treatment.

This case study highlights a 38-year-old woman with lichen planopilaris experiencing gingival hypertrophy linked to high serum cyclosporine levels and relevant dosage, which improved after reducing the cyclosporine dose.

In this study, combining flutamide with finasteride showed additive effects in reducing tumor and prostate growth in a mouse model predictive of androgen-sensitive prostate cancer.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

This study found that the extracts of Serenoa repens, when evaluated through chemical, biological, and in silico methods, demonstrated anti-inflammatory, pro-apoptotic, and anti-androgenic activities against prostate cancer cell lines, suggesting potential therapeutic benefits and directing future pharmaceutical development.

A bladder rupture from prostate treatment was healed with catheterization and antibiotics.

This review discusses current treatments for benign prostatic hyperplasia and reports on the cost-effectiveness of alpha1-selective adrenergic receptor antagonists compared to other pharmacologic and invasive therapies without presenting new clinical results.

This review discusses the pharmacology and clinical use of finasteride for benign prostatic hyperplasia and reports its effectiveness in reducing prostate size and symptoms, though success varies among patients.

This article discusses a study linking tamsulosin treatment for benign prostatic hyperplasia to a small but statistically significant increase in dementia risk compared to other treatments, without presenting new results.

This review summarizes existing studies on 5-alpha reductase inhibitors, noting their effectiveness in reducing prostate volume and cancer risk but highlighting an increased risk of higher grade prostate cancer.

Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.

This article discusses the coexistence of amyloidosis and aortic stenosis in elderly patients and explores potential therapeutic strategies, without reporting new clinical results.